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Sacral nerve stimulation (SNS) may provide long-term symptom relief to patients 
suffering chronic constipation. Patients are currently selected for SNS using a 2-
week peripheral nerve evaluation (PNE) comprising stimulation via temporary leads. 
However, only 40% of test responders receive long-term benefit from treatment 
meaning that healthcare costs per successfully treated patient are too high. The 
primary objective was to assess tined-lead testing to predict benefit from SNS for 
chronic constipation.  
Methods 
A randomised double-blind sham-controlled cross-over design evaluated enhanced 
PNE (ePNE) using tined quadripolar electrode leads over 6 weeks. The design 
differentiated between patients with discriminate and indiscriminate responses to 
testing. A score improvement of 25% or more was considered to be a positive 
response within a stimulation period. The primary outcome was the proportion of 
patients demonstrating a reduction ≥ 0.5 in constipation symptom score (PAC-SYM) 
at 6 months. 
Results 
A total of 45 patients were randomised, of whom 29 (64.4%) were test-phase 
responders. Of these, 27 were implanted providing permanent SNS. During ePNE, 
7 (18%) were discriminate responders, 22 (56%) were indiscriminate responders and 
10 (26%) were non-responders. Six patients were withdrawn during the test phase 
due to infection or non-compliance.  At 6 months, there was no significant difference 
in primary outcome between discriminate and indiscriminate responders (60% vs 
57%, p=0.76). The study was terminated prematurely due to a persistent infection 
rate of 10 (22%) during ePNE of which 9 (20%) were severe. 
Conclusions  
ePNE is a poor predictor of treatment response at 6 months. This suggests a strong 
and persistent placebo response during both SNS PNE and treatment. An extended 
6 week PNE poses a high risk of infection. 
 







Chronic constipation (CC) is present in 12-17% of the population [1] and, when mild, 
is readily managed in community settings. However, a cohort of refractory patients 
have severely impaired quality of life [2] leading to significant socio-economic costs 
[3,4 ].  Some of these patients fail to respond to conservative therapies and require 
resectional surgical procedures which are associated with high complication rates 
and uncertain efficacy [5,6].   
Sacral nerve stimulation (SNS), usually involving a temporary test followed by 
permanent implantation of a tined lead connected to a pulse generator, has been 
proposed as a less invasive treatment for patients with CC. In the UK SNS is 
approved for both faecal incontinence and urological dysfunction [7,8] but has 
insufficient evidence to support routine use for CC where the majority of studies have 
been retrospective.  Early cohort studies in CC showed high response rates (87-
90%) [9-11], but more recent studies have been less positive (33-61% response 
rates) [12,13]. One very recent high quality prospective study has suggested a very 
low response rate (19%) [14], though all patients were implanted as temporary 
testing was felt to be non-discriminatory and had been shown in a previous study to 
be compounded by a placebo effect [15]. 
Patients undergoing SNS have traditionally been selected with a 2-3 week temporary 
test (percutaneous nerve evaluation, PNE) involving the insertion of a temporary 
lead which has a single non-tined electrode. There has been a move to use a 
(permanent) tined lead as part of a two-stage, single lead procedure for urological 
disorders; the testing lead remains in place as the definitive treatment lead giving 
hypothetically better discrimination by allowing a longer duration of testing, more 
electrodes, and remaining consistent in position [16,17].  Unfortunately this may still 
not differentiate a true therapeutic response from a placebo effect. 
The basis for a further trial was that a) an enhanced testing period could identify 
and exclude placebo responses and b) even if a relatively small proportion of 
patients were accurately and reliably identified as responsive during testing, this 
would promote effective and cost-effective selection of patients for long-term 
treatment.  We planned a six-week testing phase with sub-sensory ACTIVE/SHAM 
stimulation periods with long-term follow-up to 6 months. The overall aim of the 
study was to determine whether blinded sub-sensory tined lead testing could 
correctly predict 6-month treatment response after SNS implantation. We 
hypothesised that a discriminant response during ePNE would lead to a higher 
proportion of patients defined as long-term responders (i.e. those demonstrating a 
reduction of 0.5 or more in a patient assessment of constipation symptoms score 








The TiLTS trial used a randomised double-blind sham-controlled 2-period cross-over 
design to assess response to temporary stimulation. The cross-over design 
alternated each patient between ACTIVE and SHAM sub-sensory stimulation 
periods of 2 weeks with a central 2 week washout (6 weeks in total). Patients were 
randomised [using a permuted block to ensure equal allocations] in a 1:1 ratio 
[stratified by sites] to either group A [ACTIVE (1) - SHAM (0)] or group B [SHAM (0) 
- ACTIVE (1)] order of sacral nerve stimulation during the testing ePNE phase of the 
trial, and were told that either or both periods may be active.  
Responders to each stimulation period were assessed using a simple visual 
analogue scale: TiLTS-VAS score. This scale was a 0-100 visual analogue scale of 
patients’ self-assessment of the effectiveness of the testing period in improving their 
symptoms. This score was assessed at the end (day 14) of each 2 week period 
including the washout.  A score improvement of 25% or more was considered to be 
a positive response within a stimulation period. This low threshold was chosen to 
ensure adequate numbers of patients were implanted.  
Based on their response to the two stimulation periods (ACTIVE and SHAM) patients 
were classified as discriminate responder (response to active only), indiscriminate 
responder (response to SHAM +/- ACTIVE) or non-responder (see figure 1).    
At the end of testing, patients classified as non-responders underwent removal of 
tined lead while those classified as discriminate or indiscriminate responders 
proceeded to implantation of the Interstim 2 [Medtronic US, model 3058] implantable 
pulse generator (IPG) with permanent supra-sensory sacral nerve stimulation. 
Patients with an IPG underwent follow-up assessments at 3 months while all patients 
(with or without IPG) underwent follow-up assessments at 6 months (Figure 2: 
patient flowchart). 
Patients 
Adult patients presenting for treatment of refractory idiopathic CC (using the ROME 
III criteria for functional constipation [18]) were recruited and consented. These 
patients represented treatment refractory cases who had failed medical treatments 
including multiple laxatives, prucalopride and minimally invasive treatments such as 
trans-anal irrigation and biofeedback therapy. Patients with concurrent diseases that 
could affect treatment including progressive neurological disease, or unstable doses 
of anti-cholinergic, iron supplements, antidepressants, or opioid medication, were 
excluded. Patients underwent defecating proctography as part of standard care to 





defecating proctograms. Patients with obstructed defecation were excluded. 
Baseline data were recorded including demographics, relevant medical history and 
quality-of-life (QOL). Patients were recruited from three sites in the North-East of 
England.  Two other sites which planned to recruit failed to do so due to local 
withdrawal of funding of the procedure. 
Interventions 
The surgical technique for the trial was standardised at protocol inception during an 
investigators meeting. Surgeons at each site were experienced at SNS placement 
(>100 procedures) and agreed common practice on the correct positioning of the 
tined lead and IPG using standard and established aseptic techniques. Identification 
of significant infection rates during the trial led to a thorough review and consultation 
about aseptic procedures. This review included independent microbiological review 
of the literature and culture results; a detailed root cause analysis of infected cases 
looking at factors such as surgical technique and preparation, and interviews with 
staff and experts.  Changes were made across all centres, however infections 
continued to be reported following these changes (described below). 
Patients were admitted as a day case and all procedures were performed under 
general anaesthesia with prophylactic intravenous antibiotics administered. This was 
originally Gentamycin 80mg IV within 60 minutes of skin incision. Following early 
participant infections and further expert microbiology advice this was changed to 
either [depending on MRSA status and allergies] Flucloxacillin 1G IV and 
Gentamycin 120mg IV, or Teicoplanin 400mg IV and Gentamycin 120mg IV within 
60 minutes of skin incision. The patient was positioned by the surgeon in the prone 
position. A 5mm transverse incision was made over the sacrum at the level of the 
3rd foramina to aid tined lead insertion and tunnelling of an adequate length of tined 
lead for later IPG connection. All implantable materials were soaked in Gentamycin 
solution. Under image intensified fluoroscopic guidance the testing trochar was 
inserted into the S3 foramina, and the side with the strongest low voltage anal motor 
response (bellows response) selected. The tined lead was inserted into the 3rd 
sacral foramina unilaterally and position confirmed by fluoroscopic visualisation and 
pulse stimulation of all 4 electrodes resulting in the correlating bellows response. 
The tined lead was tunnelled ipsilaterally to the buttock where a subcutaneous 
pocket (for future IPG) was formed for connection to an extension lead. This lead 
was exited on the contralateral side to minimise infection risk by ensuring an 
adequate tunnel length to the potential IPG pocket. The wounds were closed with 
absorbable sutures to the fat and subcuticular layers, and a 3MTM TegadermTM 
dressing applied to the wounds and wire to minimise infection risks. The external 
component of the exit lead was anchored to the skin with another dressing to prevent 





Participants classed as test responders proceeded to IPG implantation and 
connection of in-situ tined lead as follows; prophylactic intravenous antibiotics were 
administered as before. The lateral (potential IPG site) buttock incision was re-
opened and a suitable cavity dissected to contain the IPG. This was the ipsilateral 
side of the internally tunnelled tined lead. The extension lead was disconnected and 
discarded after removal via the exit site, with careful attention not to contaminate the 
IPG pocket. The tined lead was connected to the IPG (Interstim 2, Medtronic model 
3058) in the usual manner, and both soaked in Gentamycin solution. The wound was 
closed with absorbable sutures to the fat and subcuticular layers and a dressing 
applied. Local anaesthetic was injected around the wound edges to aid with post-
operative analgesia.  
Blinding procedures 
All investigators, the research fellow and participants were blinded to group 
allocation. Only the trials unit and a delegated un-blinded member of the research 
team at each centre were privy to the groupings. The blinding required the delegated 
team member to modify the test box at the appropriate time intervals during testing, 
and prohibited the investigators and research fellow from being involved in this 
process. Suitable training was provided to the delegated team member on stimulator 
box adjustment before commencing the trial. The un-blinded delegated team 
member performing test box adjustments was excluded from any other data 
collection as part of the trial. The blinded team members collected the assessment 
forms from the patient at the adjustment intervals, which were then used to complete 
CRFs and interpret response according to the TiLTS-cc VAS. Blinded researchers 
were aware of response, but blinded as to whether this was a discriminate or 
indiscriminate response.  
Patients were blinded successfully through use of subsensory stimulation. Their 
threshold of stimulation perception was evaluated at each adjustment interval and a 
5 minute period of nerve habituation was performed at this level. The habituated 
sensory threshold was then re-evaluated and the active subsensory stimulation was 
set to 75% of this threshold to guarantee a true subsensory test. The stimulator was 
then sealed with a unique sequential alphanumeric security seal to ensure the device 
could not be tampered with (by the participant or blinded team members through 
battery removal or device adjustment); seal voiding excluded patient data from the 
final analysis.  
External test stimulators (Medtronic models 3625 and 3531) 
During trial setup it was observed by the research team that the original analogue 
Medtronic testing SNS stimulator commonly referred to as “the brown box” by 
clinicians (model 3625), was unacceptably variable in its output waveform. An 





stimulation parameters using a cross calibrated oscilloscope (Tektronix model 2230) 
and counter-timer (Black Star Apollo 100). Consequently all model 3625 devices 
were accurately calibrated prior to each use. An identical study[20] [4] of the 
stimulation parameters of the “Verify” (model 3531) found this new digital device to 
be 4 orders of magnitude less variable, and as such was selected as the sole study 
testing device once obtained.  All patients in the study used this “Verify” model. 
Outcome measures 
The primary endpoint was the proportion of patients demonstrating a reduction of 
0.5 or more in a patient assessment of constipation symptoms score (PAC-SYM) at 
6 months. The 12-item PAC-SYM questionnaire is divided into three symptom 
subscales: rectal (three items); abdominal (four items) and stool (five items). Items 
are scored on 5-point Likert scales, with scores from 0 to 4 (0 ‘symptom absent’ - 4 
‘very severe’). A mean total score from 0-4 is generated by dividing the total score 
by the number of questions completed; the lower the total score, the lower the 
symptom burden [21]. Secondary endpoints included number of discriminant and 
non-discriminant responders, scores from daily diary exercises, quality of life 
(measured using PAC-QOL, EQ-VAS, TilTS-VAS and Euro-QOL-5D), and 
constipation symptoms scores (Cleveland clinic questionnaire and Wexner Score).  
Adverse events 
Patients were monitored for procedure-related adverse events and complications. 
Adverse events were recorded from the beginning of day 1 of trial intervention, until 
completion of phase 3. These were reviewed on a regular basis by an independent 
data monitoring committee. Adverse events were summarised and tabulated. 
Sample Size 
From audit data, we estimated that 40% of patients would have a discriminate 
response to testing, and 70% of those would continue to benefit at 6 months. For the 
60% of patients with an indiscriminate response, we estimated 20% would respond 
at 6 months. Assuming 90% power, alpha = 5%, and an allocation ratio of 1:1.5, the 
trial sample size required for responders was 50. Allowing for loss to follow-up of 
20% the required sample size was 60 responders.  Assuming 20% of patients failed 
to respond, the sample size (of responders and non-responders) required was 75.   
Statistical analyses 
All analyses of the continuous efficacy endpoints were based on mixed effects 
models. Study groups were tested at the 2-sided 5% significance level. All analyses 





generalised estimating equations for secondary binary endpoints. Analysis was 
performed in SAS® 9.4 and R v3.2.3. 
Trial registration 
The trial was registered with the International Clinical Trials Registry Platform 
(http://apps.who.int/trialsearch) with a registration number ISRCTN44563324 
(http://www.isrctn.com/ISRCTN44563324).   
Ethical approval 
The study was approved by the NRES Committee North East-York, REC reference 
number 12/NE/0228 on 24/08/2012. A Trial Steering Committee provided study 
oversight and an independent Data Monitoring Committee met to review data regularly 
throughout the study.  
 
Results 
The trial was terminated prematurely due to a persistent and unacceptably high 
serious infection rate (see below). A total of 45 patients were randomised from the 
target of 75. Data on all randomised patients are shown in table 1. Of the total, 43 
(96%) were female with a median age of 40yrs (range: 18yrs to 68yrs) and a median 
duration of constipation symptoms of 18yrs (range: 3yrs - 45yrs). At baseline, 
patients had a high constipation symptom burden (PAC-SYM mean score 2.19 
±0.86; PAC-QoL mean score 2.70 ±0.82), the majority had slow transit (n=30; 67%) 
and high comorbidity; a total of 37 (82%) patients had at least one co-morbidity with 
a median of 2 (range: 1-9) patients per co-morbidity. The most common reported co-
morbidities were anxiety and depression.  
Response to interventions 
10 patients (26%) were non-responders (table 2) and were not implanted in 
accordance with the protocol. A total of 6 patients were withdrawn during ePNE (1 
due to non-compliance, and 5 due to lead site infection. Twenty-nine patients (29/45: 
64.4%) were responders to the testing phase. Of these, 7 (18% total) were 
discriminate responders and 22 (56% total) were indiscriminate responders. Of the 
29 responders, 27 were implanted with a permanent IPG (2 were not implanted; 1 
patient declined and 1 had a lead site infection precluding implantation) (Fig 2: 





Clinical outcomes  
A total of 33 patients were followed up to 6 months (see figure 2). A total of 15 
(57.7%) patients with IPG responded to SNS treatment at 6 months based on the 
primary endpoint. Five patients (71.4%) without IPG also showed a reduction of more 
than 0.5 in PAC SYM score.  The Quality of life score (PAC-QOL) improved at 12 
weeks but deteriorated at 6 months follow-up (figure 3), while other scores 
(Cleveland and Wexner) showed improvements at 6 months (figure 4). Table 3 
suggests small improvements in constipation symptoms among patients with IPG. 
Prediction of 6 month clinical outcome. 
At 6 months there was no significant difference between discriminate and 
indiscriminate responders (60% vs 57%, p=0.76) in meeting the primary endpoint 
(≥0.5 point reduction in PAC SYM score, Table 4).  
The TiLTS VAS score at 2 and 6 weeks during ePNE was evaluated as a prognostic 
measure for response at 6 months (PAC-SYM) but failed to identify patients more 
likely to benefit from SNS treatment (active - sham: 3% 95%CI: -45% to 51%). TiLTS 
VAS did not discriminate well between responders and non-responders at 6 months: 
Sensitivity = 75.0% (95% CI: 56.0% to 94.0%), Specificity = 15.4% (95% CI: 0.0% to 
35.0%), Positive Predictive Value = 57.7% (95% CI: 38.7 to 76.7%), Negative 
Predictive Value = 28.6% (95% CI: 0.0%-62.0%), (Table 5). The failure to 
discriminate between the active and sham phases is illustrated in Figure 5.  
A key design feature was the sub-sensory, blinded stimulation. Figure 6 shows no 
significant differences during the testing phase by timing or sequence confirming that 
blinding was successful. 
Adverse events 
During testing and follow-up phases, there were a total of 103 adverse events 
experienced by 40 (89%) patients, of which 56 events were considered related to 
the trial (Table 6). Of the related events, 11 were severe. There were a total of 10 
infections, of which 9 were severe and led to urgent removal of the tined lead during 
testing phase (n=6, 13% of 45) or IPG (n=3, 11% of 27). The one superficial infection 
responded to treatment during the testing phase. Of the 3 infections affecting those 
with IPGs, all were late (>4 months following implantation) with one identified at the 
6-month follow-up. Changes in surgical practice failed to reduce the infection rate.  
Two patients became pregnant during the study contrary to protocol and participant 
information sheet advice; both resulted in live births of which one has a diagnosis of 






The initial enthusiasm for SNS in constipation produced by early studies has been 
tempered by later reports suggesting very low response rates. Most recently two 
prospective randomised studies have been completed [14, 22] showing poor 
response rates and no difference between sham and active intervention for primary 
outcomes. These findings have mirrored both our own clinical experience in over 50 
patients followed over 3-4 years (unpublished audit data) and also findings from 
recent systematic reviews of SNS for both constipation and faecal incontinence 
[23,24]. If there were effective alternative treatments for these patients there would 
be little benefit from further study. But patients considered for SNS are, by definition, 
refractory to all other conservative measures and have symptoms which produce a 
major impact on well-being.  Thus, even if a minority of patients benefit, the treatment 
would be a valuable therapeutic option if long term responders could be accurately 
identified by temporary testing.  The predictive value of temporary testing seems 
reasonable in faecal incontinence [25], but possibly less effective in patients with 
constipation.  We sought to design a testing process which could be used in routine 
clinical practice and which would differentiate placebo and therapeutic response. 
The profiles of patients on SHAM and ACTIVE stimulation periods were similar, 
suggesting that blinding was successful.  The results confirmed what is already 
known: that subjective assessment of response (in this case through a visual 
analogue scale) is a poor predictor of long term outcome.  In this study we used a 
low threshold (25% improvement) to determine patients who would receive an 
implanted device.  This was to make sure enough patients were implanted and allow 
for that fact that temporary testing might give false negatives as well as false 
positives.  A post-hoc analysis was conducted looking at those patients who had 
scored 50% or more on the VAS – a more typical threshold for decision to implant – 
but this analysis (not shown) did not alter our conclusions (Table 7&8).  
The analysis of discriminate and indiscriminate responses was disappointing.  In fact 
21/26 (81%) of implanted patients had indiscriminate responses (i.e. had responded 
to the SHAM stimulation) and importantly discriminate responses were no better at 
identifying improved long term response.  Possible causes for this are that sub-
sensory stimulation is inadequate as a test of response, or that the long term 
responses are themselves prolonged placebo responses. 
The trial was terminated early due to a high and persistent infection rate, precluding 
conclusions about overall efficacy and completion of planned analyses of secondary 
outcomes and health economic analysis.   
Fifteen (56%) implanted patients were responders at six months according to a 0.5 
point drop in PAC-SYM.  This may be challenged as most studies using PAC-SYM 





the minimum clinically important difference for PAC-SYM is -0.65 [21].  Thus, the 
proportion of responders we report is very much an upper limit both in terms of 
threshold of response and the fact that this was assessed at 6 months, beyond which 
we would expect some drop-off in effect as shown in the study by Patton et al [14].  
These factors undermine further the responder rate, which is relatively modest, and 
suggest that a valuable treatment response is unlikely.  The mean values for 
changes to outcome variables (PAC-SYM, PAC-QOL, EQ5D, EQVAS and 
Cleveland Clinic Score) were modest and imprecise.  The mean PAC-QOL was most 
improved at 3 months and then deteriorated at 6 months, possibly suggesting a drop-
off of effect, chance effect, or a placebo response. 
The infection rate (22%) was higher than expected and most infections were severe.  
This led to a thorough review of aseptic procedures (including external consultation), 
expert review of antibiotic prophylaxis and a root cause analysis of the first 8 
infections.  The stringency of surgical aseptic procedures and antibiotic prophylaxis 
were increased and appropriate amendments made to the study protocol.  Despite 
these, further infections occurred and the Chief Investigator and Trial Steering 
Committee decided to terminate the study.  The infection rate in patients having SNS 
for faecal incontinence in the sites undertaking the TiLTS trial is <3%.  This was 
audited during the time of the study as part of the root cause analysis and confirmed 
to be low. The method of percutaneous testing for faecal incontinence used the 
standard 2-week test period, with explanting of the temporary lead and re-
implantation of a tined lead for permanent stimulation. It follows that the cause of the 
high infection rate seen in the TiLTS study was related to the prolonged use of 
percutaneous lead testing. 
Initial studies of single lead 2-stage tined lead testing have focussed on efficacy 
[16,17] with little mention of adverse events, but a larger and more recent study has 
emphasized a higher rate of infection, reported to be 12% [26].  Our experience 
leaves cause for concerns about the safety of tined lead testing, which is now 
becoming more popular in clinical urological practice.  There is a possibility that a 
single lead procedure will always pose a higher risk as the lead is externalised for a 
period of time and so can become sub-clinically contaminated, leading to infection 
at a later time.  Dudding and Vaisy [27] sought to understand this risk by culturing 
the tip of temporary stimulation leads which had been in place for a mean of 21 days 
and found that 7/13 (54%) were colonised by bacteria. 
Our study has a number of limitations.  The early cessation of the trial, with 45 
patients recruited, was 30 patients short of the target and has meant that definitive 
conclusions on long term efficacy are tentative.  The predictive failure of discriminate 
testing could be related to the cut-off used to denote a test responder.   
Despite these reservations the data are in keeping with the most recent prospective 





constipation and that high placebo response rates occur in temporary testing, 
irrespective of attempts to reduce this.  Importantly we have found a very high 
infection rate using 6-week tined lead temporary stimulation despite considerable 
attempts to reduce this risk.  We believe that the extended use of tined lead testing 
requires further safety assessment before widespread use. 
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Table 1: Trial Population Baseline Characteristics 
1 PAC-SYM: Patient Assessment of Constipation-Symptoms 
2 PAC QoL: Patient Assessment of Constipation Quality of Life questionnaire 
3 EQ-VAS: Quality of Life Visual Analogue Scale 





Characteristics Number (%) Mean ± SD Median(Min-
Max) 
Total number  45 (100%) - - 
Female  43 (96%) - - 
Age  45 (100%) 40.9±13.5 40.0(18.0 - 68.0) 
PAC SYM1 45 (100%) 2.19±0.86  
PAC QoL2 45 (100%) 2.70±0.82  
EQ-VAS3 45      (100%) 50.93±18.40  
EQ-5D4 40        (89%) 0.48±0.37  
Duration of constipation 
symptoms 
45 (100%) 17.64±11.14 18.0(3.0 – 45.0) 
Currently treated for 
constipation  
42 (93%) - - 
Other comorbid conditions 37 (82%) 2.81±1.96 2.0 (1.0 – 9.0) 
Current Mental ill-health 13 (29%) - - 
Previous Appendicitis 7 (16%) - - 





Table 2: Response to active/sham testing (n=391) 
Active Sham Response N1 
+ - Discriminate 7 
+ + Indiscriminate 18 
- + Indiscriminate 4 
- - No response 10 




Table 3: Secondary outcomes comparing difference from baseline at 2, 4, 6, 
12 and 24 weeks FOR IPG PATIENTS ONLY  (n=27) 
 Weeks (mean score (95% CI) 
Outcome 2 4 6 12 24 
PAC SYM1 -0.57(-0.86,-0.27) -0.45(-0.75, -0.15) -0.85(-1.15, -0.54) -1.03(-1.39, -0.07) -0.69(-1.00, -0.37) 
PAC QOL2      
ALL    -0.84(-1.19, -0.48) -0.50(-0.82, -0.17) 
Physical    -1.56(-2.13, -0.98) -0.62(-1.14, -0.10) 
Psychosocial    -1.10(-1.64, -0.56) -0.68(-1.18, -0.19) 
Worries    -1.22(-1.70, -0.75) -0.66(-1.10, -0.22) 
Satisfaction    -0.98(0.61, 1.35) 0.27(-0.09, 0.62) 
EQ5D4    0.21(0.03, 0.38) 0.10(-0.05, 0.25) 
EQVAS3    15.5(3.13, 27.87) 3.77(-8.34, 15.88) 
Cleveland     -0.54(-0.76, -0.32) 
1 PAC-SYM: Patient Assessment of Constipation-Symptoms 
2 PAC QoL: Patient Assessment of Constipation Quality of Life questionnaire 
3 EQ-VAS: Quality of Life Visual Analogue Scale 








Table 4: Response to SNS at 6 months (PAC SYM >=0.5) according to 
discriminate/indiscriminate response at 6 weeks (n=26) 
TiLTS-cc_VAS 
Classification 
Reduction in PAC SYM >= 0.5  




3(60.0) 2(40.0) 5 
Indiscriminate 
Responder 
12(57.1) 9(42.9) 21 
RD = 0.03(-0.45, 0.51),  P-value =  0.7586 
 




Reduction in PAC SYM >= 0.5  
Total Responder (%) Non-Responder 
(%) 
Responder 15(57.7) 11(43.3) 26 
Non Responder 5(71.4) 2(28.6) 7 
Sensitivity(%) = 75.0(56.0, 94.0),  Specificity(%) = 15.4(0.0, 35.0 ) 
PPV(%) = 57.7(38.7, 76.7),  NPV = 28.6 (0.0, 62.0) 
 
Table 6: Adverse events according to severity 
Category Number of events  Number of patients (%) 
Adverse events (All)  103 40 (89%) 
Related to study intervention 56 40 (89%) 
Severe and related 11 11 (24%) 
Infections (related)  10 10  (22%) 
Severe infections leading to 
tined lead removal during 
testing phase 
6 6 (13%) 
Severe infections leading to 
IPG removal during follow-up 







Table 7: Response to SNS at 6 months (PAC SYM >=0.5) according to 




Reduction in PAC SYM >= 0.5  




2(50.0) 2(50.0) 4 
Indiscriminate 
Responder 
10(66.7) 5(33.3) 15 
RD = -0.17(-0.71, 0.37),  P-value =  0.6027 
 
 





Reduction in PAC SYM >= 0.5  
Total Responder (%) Non-Responder 
(%) 
Responder 12(63.2) 7(36.8) 19 
Non Responder 8(57.1) 6(42.9) 14 
Sensitivity(%) = 60.0(36.1, 80.9),  Specificity(%) = 46.2(19.2, 74.9) 









Figure 1 Algorithm of temporary testing and classification  



























Follow-up at 3 months 
and 6 months (N=26)
Withdrawals:
Lead site infection (n=5)
Non-compliance (n=1)
Patients on usual treatment 
(n=10)






Responders to test phase
(N=29)




Lead site infection (n=1)
Loss to follow-up:






Figure 3: PAC QoL scores (means) from baseline to 6 months  
for IPG patients 
 
 
Figure 4: Cleveland and Wexner scores from baseline to 6 months  













Figure 6: PAC SYM average profiles by randomisation order for IPG patients
 
NB: active +/- sham stimulation occurs only during week 0-6 
 
